Ripple (XRP) is facing more pressure following the resignation of its CTO, leaving investors questioning short-term price momentum. With the uncertainty lingering, savvy investors have turned attention to Mutuum Finance (MUTM), a feature-rich DeFi altcoin priced at $0.035, which has already sold over 55% of its Phase 6 presale. Through its dual lending ecosystem, real-yield […]Ripple (XRP) is facing more pressure following the resignation of its CTO, leaving investors questioning short-term price momentum. With the uncertainty lingering, savvy investors have turned attention to Mutuum Finance (MUTM), a feature-rich DeFi altcoin priced at $0.035, which has already sold over 55% of its Phase 6 presale. Through its dual lending ecosystem, real-yield […]

Is Ripple’s CTO Resignation Bearish for XRP Price? Key Levels to Watch Now and the 50x Crypto on Investors’ Radar

2025/10/04 01:30
4 min read

Ripple (XRP) is facing more pressure following the resignation of its CTO, leaving investors questioning short-term price momentum. With the uncertainty lingering, savvy investors have turned attention to Mutuum Finance (MUTM), a feature-rich DeFi altcoin priced at $0.035, which has already sold over 55% of its Phase 6 presale. Through its dual lending ecosystem, real-yield tokenomics, and non-custodial smart contracts, MUTM is garnering both whale and retail interest, with the potential for 50× upside. The increasing demand makes Mutuum Finance one of the most promising high-reward projects on investors’ radar going into the next market cycle.

XRP at a Critical Juncture as CTO Steps Down

XRP is now trading around $2.86, under pressure after it printed a Head & Shoulders pattern on the 1-hour chart, a bearish signal that has traders on red alert. Support areas of major concern are $2.83 and $2.79, while resistance is at $2.87 and $2.91. Not being able to sustain support would shift momentum further bearish, while reclaiming $2.91 would void the pattern and leave the door ajar for continuation higher. 

Adding to the uncertainty, Ripple’s legendary CTO David Schwartz is retiring after 13+ years, though he will remain engaged as CTO Emeritus and join the Board of Directors, so his influence on the project will persist. As XRP reaches its moment of truth, investors are turning increasingly to the market for emerging utility-driven projects such as Mutuum Finance (MUTM), which are building momentum for their upside potential amidst general market volatility.

Mutuum Finance Presale Gains Momentum

Mutuum Finance is generating even more hype and anticipation for its presale, with the platform having already raised over $16.7 million and more than 16,710 investors on board to date. Stage 6 of the project is now ongoing, during which MUTM tokens are available to buy at $0.035 per token. As a reward for early adopters, Mutuum Finance is conducting a $100,000 giveaway promotion, whereby 10 users will be awarded $10,000 worth of MUTM tokens each.

In accordance with continued security and transparency, Mutuum Finance has collaborated with CertiK to launch a $50,000 USDT Bug Bounty Program. The program rewards white-hat hackers and security researchers for discovering bugs in the protocol codebase. Bugs are ranked according to severity as minor, low, major, or critical, and corresponding rewards are given to contributors.

The protocol will have a dynamic floating interest rate mechanism that maximizes the utilization of liquidity. Low interest rates and times of excess liquidity encourage borrowing and ecosystem activity and times of higher demand and elevated interest rates encourage repayment of loans and incoming capital flows. Fixed interest models function optimally when liquidity is constant, adjusting automatically to overall market forces.

As a fully decentralized system, Mutuum Finance empowers the holders of the MUTM token. Lending and borrowing are decoupled from the rest of the system and are supported by an interest rate mechanism that maximally exploits long-term efficiency, promotes diversification of portfolios, and increases with higher overall DeFi market expansion.

Profitable lending, borrowing, and liquidation require efficient valuation of assets. To this effect, Mutuum Finance uses Chainlink oracles to obtain real-time USD and major crypto asset prices such as ETH, MATIC, and AVAX. The platform maximizes data precision using fallback oracle systems, composite data feeds, and time-weighted averages from decentralized exchanges to ensure sound valuations during the highly volatile and distressed market conditions.

MUTM Stands Out Amid XRP Uncertainty

Mutuum Finance (MUTM) is rapidly emerging as a high-upside DeFi opportunity, raising over $16.7 million from more than 16,710 investors in its Phase 6 presale, which is now over 55% sold. Tokens are presently priced at $0.035, with early buyers afforded the ability to get in before the price is increased in the subsequent phase. The platform combines a dual lending ecosystem, dynamic interest rates, and Chainlink-enabled asset valuations to offer both security and efficiency. To complement these features, a $50,000 bug bounty and $100,000 early-adopter giveaway reinforce investor trust and participation. Getting in early on the presale positions investors to profit from this rapidly evolving DeFi ecosystem.

For more information regarding Mutuum Finance (MUTM) please use the following links:

Website: https://mutuum.com/

Linktree: https://linktr.ee/mutuumfinance

Market Opportunity
XRP Logo
XRP Price(XRP)
$1.4178
$1.4178$1.4178
-1.95%
USD
XRP (XRP) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của CEO Bitget Gracy Chen Trở Thành Hiện Thực Và Tầm Nhìn Về Đích Đến 5.400 USD

Thị trường tài chính toàn cầu vừa chứng kiến một khoảnh khắc lịch sử chấn động: Giá Vàng thế giới [...] The post Vàng Cán Mốc Lịch Sử 5.000 USD: Khi Dự Báo Của
Share
Vneconomics2026/02/10 16:26
Why the Bitcoin Boom Is Not Another Tulip Mania

Why the Bitcoin Boom Is Not Another Tulip Mania

Bitcoin is an amazing success story. It was only invented in January of 2009 and was only worth a tiny fraction of a cent for each token. Over just a few years
Share
Medium2026/02/10 15:44
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26